Key inclusion criteria require advanced unresectable hepatocellular carcinoma (histologically confirmed) with Child-Pugh class A, ECOG 0-1, and contraception use. Exclusions cover prior liver transplant, uncontrolled portal hypertension, CNS metastases, active HBV/HCV/HDV/HIV co-infections, recent cardiovascular events, additional malignancies within 2 years, >2 prior systemic therapies (Part 2 restrictions), concurrent anticoagulation, recent radiotherapy, major allergies, and protocol-specified contraindications. Full eligibility details are available via BMSStudyConnect.com.

Efficacy assessments include Best Overall Response (BOR, requiring confirmation scan), Overall Response Rate (ORR), Duration of Response (DoR), Progression-Free Survival (PFS), and PFS rates at predefined intervals (12, 24, 36 weeks). Pharmacokinetic analysis focuses on Cmax, Tmax, AUC (0-T and TAU), Ctrough, CLT, Vss, Vz, accumulation indices (AI_Cmax, AI_Ctau, AI_AUC (TAU)), Css,avg, and T-HALF for BMS-986183 components (total antibody, active ADC, tubulysin) as monotherapy and with nivolumab. Additional endpoints include QTcF changes from baseline and anti-drug antibody (ADA) incidence.

Eligible adults (≥18 y, ECOG 0-1) must have CDH3-expressing metastatic solid tumors, measurable lesions (RECIST 1.1), ≥3-month life expectancy, and adequate organ function. Exclusions include prior allogeneic transplants, uncontrolled hypertension, active CNS metastases, ocular/cardiac/pulmonary comorbidities, recent immunosuppression or CYP3A4 modulators, or pregnancy. Contraception is mandatory for 6 months post-treatment.

Eligible participants (≥18 years, ECOG 0-1) must provide informed consent and have metastatic solid tumors refractory to standard therapies with ≥3-month life expectancy. Key exclusions include pregnancy, recent anticancer treatment, uncontrolled hypertension, active infections, cardiovascular disease, or poor compliance potential as judged by investigators. Effective contraception is required for 6 months post-treatment.

Eligible patients must be &ge;19 years old with ECOG 0-1, adequate organ function (hematologic/renal/hepatic), and negative pregnancy status. Key exclusions include trastuzumab intolerance, active CNS metastases, unresolved Grade &ge;2 toxicities, recent anticancer therapies (<3 weeks), significant cardiopulmonary dysfunction (LVEF<50%, NYHA II-IV), active infections (HIV/HBV/HCV), or other malignancies within 5 years (except specified cured cancers).

The study evaluates safety endpoints including dose-limiting toxicities (DLTs) during the 21-day assessment period to determine maximum tolerated dose (MTD) or recommended phase II dose (RP2D), along with treatment-emergent adverse events (TEAEs) graded by CTCAE v4.03 with special focus on immune-related adverse events (irAEs) monitored for up to 4 weeks post-treatment.

Eligible patients must be &ge;19 years old with ECOG 0-1, adequate organ function (hematologic/renal/hepatic), and negative pregnancy status. Key exclusions include trastuzumab intolerance, active CNS metastases, unresolved Grade &ge;2 toxicities, recent anticancer therapies (<3 weeks), significant cardiopulmonary dysfunction (LVEF<50%, NYHA II-IV), active infections (HIV/HBV/HCV), or other malignancies within 5 years (except specified cured cancers).

The study evaluates safety endpoints including dose-limiting toxicities (DLTs) during the 21-day assessment period to determine maximum tolerated dose (MTD) or recommended phase II dose (RP2D), along with treatment-emergent adverse events (TEAEs) graded by CTCAE v4.03 with special focus on immune-related adverse events (irAEs) monitored for up to 4 weeks post-treatment.

Eligible participants must be &ge;18 years with ECOG 0-2, &ge;12-week life expectancy, confirmed advanced solid tumors refractory to standard therapy, and evaluable disease. Required lab values include: Hgb>10, ANC&ge;1500, platelets&ge;100K, bilirubin&le;1.5xULN, ALT/AST&le;2.5xULN (5x if liver mets), creatinine&le;1.5xULN. Exclusions include significant cardiac disease (CHF III/IV, recent MI, arrhythmias, LVEF<40%), pancreatic abnormalities, uncontrolled HTN, active CNS mets (<6mos stable), renal failure, active HBV/HCV/HIV, grade&ge;3 infections, unhealed wounds, drug allergies, or other malignancies (except cured cancers >3yrs prior).

Eligible patients must be &ge;18 years old with ECOG 0-2, &ge;12-week life expectancy, and advanced refractory solid tumors (histologically confirmed) who either lack standard options or decline standard therapy, with evaluable disease and adequate organ function. Key exclusions include significant cardiac disease (CHF Class III/IV, recent MI, unstable angina), uncontrolled hypertension (>160/95 mmHg), untreated CNS metastases, severe renal impairment, active HBV/HCV/HIV infections requiring treatment, serious unhealed wounds, recent major surgery/trauma, or anticancer treatments within protocol-specified washout periods.